Are calcium channel blockers safe in diabetes?
Calcium channel blockers may be of additional potential benefit to the diabetic patient by slowing the progression of atherosclerosis, reversing the intracellular calcium defects that may contribute to the pathogenesis of diabetic cardiomyopathy, and protecting against the progression of chronic renal disease.
Why can’t diabetics take calcium channel blockers?
Aims. Insulin resistance and the progressive loss of β-cell function are components of the fundamental pathophysiology of type II diabetes. A recent experimental study suggested that calcium channel blockers (CCBs) might inhibit β-cell apoptosis, enhance β-cell function, and prevent diabetes.
Are calcium channel blockers contraindicated in renal failure?
Non-dihydropyridine calcium channel blockers (CCBs) are recommended for hypertensive patients but not for those with CKD, according to the JNC 8 guidelines; however, a meta-analysis demonstrated that CCBs reduce not only BP but also proteinuria[5].
Which drug is used as a CCB Nondihydropyridine to treat hypertension?
Diltiazem is a nondihydropyridine CCB that produces its antihypertensive effect primarily by relaxation of vascular smooth muscle and the resultant decrease in peripheral vascular resistance. The magnitude of blood pressure reduction is related to the degree of hypertension.
Do Calcium channel blockers affect blood sugar?
The results of the study showed that those who used calcium channel blockers had 5 mg/dL lower serum glucose than those who didn’t use. While verapamil users had an average of 10 mg/dL lower serum glucose in comparison to calcium channel blocker non-users.
Can calcium channel blockers cause high blood sugar?
Background: Overdoses of calcium channel blocker agents result in hyperglycemia, primarily due to the blockade of pancreatic L-type calcium channels and insulin resistance on the cellular level. The clinical significance of the hyperglycemia in this setting has not previously been described.
Is verapamil safe for kidneys?
Renal blood flow increased significantly and there was a significant increase in uricosuria and a subsequent decrease in plasma uric acid levels. In conclusion, verapamil SR is an effective and well tolerated treatment for hypertension associated with chronic renal failure.
Is verapamil a non dihydropyridine?
Non-dihydropyridines — The non-dihydropyridines, including verapamil and diltiazem, are used in the management of hypertension, chronic stable angina, cardiac arrhythmias, or for proteinuria reduction.
What type of CCB is verapamil?
Verapamil is an l-type calcium channel blocker used in the treatment of hypertension, angina pectoris, cardiac arrhythmia.
What does non dihydropyridine mean?
Nondihydropyridines are one of the different types of calcium channel blockers; they act mainly on the heart with less effect on blood vessels. They have a greater depressive effect on cardiac conduction and contractility but are less potent vasodilators than other types of calcium channel blockers (dihydropyridines).
Does verapamil affect diabetes?
A new study shows the drug, verapamil, appears to protect pancreatic cells that produce insulin. A cheap and safe blood pressure drug slows the worsening of Type 1 diabetes, researchers reported Monday.
Does verapamil affect blood sugar?
Those taking verapamil had lower fasting blood glucose levels, about 10 mg/dL lower than the non users. The biggest difference was found between those on insulin taking verapamil, who averaged a blood glucose of 118 mg/dl, compared to non users of any calcium channel blockers, who had an average blood glucose of 156.
Is verapamil safe for diabetics?
Verapamil was the most common agent studied. Non-DHP CCBs were effective in reducing proteinuria in diabetic kidney disease but did not reduce renal or cardiovascular outcomes in the one trial that evaluated clinical end points. They were generally well tolerated, with the most common adverse effect reported being constipation.
How effective are non-DHP CCBs in diabetic kidney disease?
Non-DHP CCBs were effective in reducing proteinuria in diabetic kidney disease but did not reduce renal or cardiovascular outcomes in the one trial that evaluated clinical end points. They were generally well tolerated, with the most common adverse effect reported being constipation.
What is the difference between DHP and non-DHP CCBs?
Experimental studies and a limited number of clinical studies suggest that non-DHP CCBs, including verapamil and diltiazem, have a mechanism of action that differs from DHP CCBs. Non-DHP CCBs could potentially attenuate sympathetic activity and reduce protein excretion in patients with CKD. Publication types
Are non-DHP CCBs effective in the treatment of proteinuria?
The literature does suggest non-DHP CCBs can also be effective and are a reasonable option for patients who cannot tolerate or have a contraindication to ACE-Is or ARBs. These treatment options would also likely benefit patients on maximally tolerated ACE-Is or ARBs, but continue to have progression of proteinuria.